Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report) shares were up 7.8% during mid-day trading on Wednesday . The company traded as high as $0.20 and last traded at $0.19. Approximately 19,100 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Price Performance
The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.86 and a current ratio of 2.86. The firm has a 50 day simple moving average of $0.19 and a 200-day simple moving average of $0.19.
About Vyant Bio
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
See Also
- Five stocks we like better than Vyant Bio
- How to trade using analyst ratings
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 2 Drone Stocks Surging from Increased Media Attention
- Are Penny Stocks a Good Fit for Your Portfolio?
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.
